Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

Children with cancer can often be successfully treated with chemotherapy drugs that can unfortunately damage the heart in the process. Development of an effective method to prevent this type of injury while curing the cancer is very important. This consortium's goal is to give children successfully cured of cancer the greatest chance of having a completely healthy life afterwards, free of treatment-related side effects. The study is to determine whether a drug called dexrazoxane, which appears to be safe and effective in adults in preventing chemotherapy-related heart injury, can be similarly safe and effective when used in children. Funds administered by Fred Hutchinson Cancer Research Center.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

The concept of resilience implies an ability to withstand stress after a significant crisis. While there are several theories of resilience, there is little consensus about how to define it or, more importantly, how to promote it. Cancer in children and adolescents can pose daunting challenges for patients as well as their families. This study explores a novel model of resilience among adolescents and parents of children with cancer. Promoting resilience during and after childhood cancer will promote more positive psychosocial outcomes and ultimately enable better family-level survivorship.

Based on progress to date, Dr. Nakamura, was awarded a new grant in 2016 to fund an additional year of this Scholar award. Survivors of childhood cancers are susceptible to developing second malignant neoplasms, which are complications of cancer treatments. Dr. Nakamura's lab has developed new experimental models that closely replicate this clinical problem, which they are using to study the biologic basis for second malignant neoplasms. This research improves the understanding of the genetic and biochemical mechanisms causing second malignant neoplasms, which may lead to improved cancer prevention strategies for childhood cancer survivors and the general population. A portion grant is generously supported by the Morgan and Friends Fund, a St. Baldrick's Hero Fund, created to honor Morgan Loudon. It celebrates her strength and determination as a cancer survivor while rallying family and friends to “battle on” in the search for cures and better treatments.

Having friends is vitally important for all children. Children surviving brain tumors often have physical problems (jerky movements, slurred speech, etc.) and cognitive delays caused by their disease or treatment. These cancer survivors are frequently described by peers as "not well liked," "having few friends" and "isolated". This puts them at risk for being bullied, dropping out of school, becoming anxious or depressed, and being less likely to marry or have good jobs as adults. Dr. Noll is conducting a research-backed, school-based project to support brain tumor survivors' social involvement by training classmates to be more inclusive of others viewed as "different."

Dr. Phipps is studying what happens to children who were treated with bone marrow transplant for cancer many years ago. This is a very challenging treatment that can cause problems for survivors in a number of areas, including their thinking and learning ability, their physical health, and their ability to have children. He is learning how these children and young adults are faring relative to their healthy peers, to identify factors that lead to better or poorer outcomes so that researchers can develop treatments to prevent any negative effects.

Childhood cancer survivors are at risk for developing long term health problems including heart disease. Dr. Ruble's research finds ways to make survivors healthy by participating in physical activity. Currently less than 50 percent of survivors participate in adequate amounts of exercise, which increases the risk of developing health problems. This project aims to find out the best way to support survivors in changing behaviors and being healthy.

Even though more and more children are being cured of cancer, the treatment can cause major life-long health problems for survivors. Unfortunately, most adult survivors don't seek appropriate medical care to monitor and care for these problems. This project is to study whether or not adult survivors referred to adult-focused follow-up care actually engage in such care and what might get in the way of doing so. The results of the study will help medical providers better prepare young adult survivors to engage in adult-focused follow-up care to assure that they stay as healthy as possible.

About 80% of children and adolescents diagnosed with cancer become long-term survivors. About half of them develop therapy-induced hearing loss that is cumulative and irreversible. Most at risk are patients with brain tumors, neuroblastomas, osteosarcomas, soft tissue sarcomas, retinoblastomas, hepatoblastomas, or germ cell tumors who need to be treated with cisplatin, combinations of cisplatin and carboplatin, radiation to the head and neck, or combinations of platins and radiation. Therapy-induced hearing loss adversely affects speech and language development, reading ability, communication, academic performance and psychosocial development. It frequently causes stress, social isolation, low self-esteem, and low overall quality of life. This project explores the use of moderate to high doses of dietary selenium as means to reduce or prevent cisplatin-induced hearing loss.

Although most children with leukemia can be cured, chemotherapy frequently causes permanent brain dysfunction in survivors. With previous support from St. Baldricks, Dr. Cole's lab identified promising protective interventions, and he will now test them among those children at greatest risk for brain damage. To identify this population researchers are studying whether variation in neurocognitive function among leukemia survivors is related to specific inherited differences in genes related to repair mechanisms or to metabolism of drugs thought to cause cognitive deficits.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Comprehensive Approach to Improve Medication Adherence in Pediatric ALL. For a description of this project, see the consortium grant made to the lead institution: the University of Alabama at Birmingham, Birmingham, AL.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Comprehensive Approach to Improve Medication Adherence in Pediatric ALL. For a description of this project, see the consortium grant made to the lead institution: the University of Alabama at Birmingham, Birmingham, AL.

One of 5 children with acute lymphoblastic leukemia suffers a relapse within 5 years of diagnosis. Also, Hispanic and African American children are more likely to relapse. Research has shown that 44% of the children are non-adherent to oral chemotherapy and that non-adherence is associated with an increased risk of relapse. This consortium has created a comprehensive package of interventions to improve adherence to oral chemotherapy. It is believed that this improvement in adherence will directly translate into an improvement in survival and a higher number of children cured of their cancer. Awarded at the Beckman Research Institute of the City of Hope and transferred to the University of Alabama at Birmingham. Funds administered by the University of Alabama at Birmingham.